ES2350495T3 - Forma cristalina de un compuesto de quinolinona-carboxamida. - Google Patents

Forma cristalina de un compuesto de quinolinona-carboxamida. Download PDF

Info

Publication number
ES2350495T3
ES2350495T3 ES06740692T ES06740692T ES2350495T3 ES 2350495 T3 ES2350495 T3 ES 2350495T3 ES 06740692 T ES06740692 T ES 06740692T ES 06740692 T ES06740692 T ES 06740692T ES 2350495 T3 ES2350495 T3 ES 2350495T3
Authority
ES
Spain
Prior art keywords
crystalline
salt form
crystalline salt
oxo
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06740692T
Other languages
English (en)
Spanish (es)
Inventor
Paul R. Fatheree
Adam Goldblum
S. Derek Turner
Daniel Genov
Robert Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ES2350495T3 publication Critical patent/ES2350495T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES06740692T 2005-04-06 2006-04-05 Forma cristalina de un compuesto de quinolinona-carboxamida. Expired - Lifetime ES2350495T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US668780P 2005-04-06

Publications (1)

Publication Number Publication Date
ES2350495T3 true ES2350495T3 (es) 2011-01-24

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06740692T Expired - Lifetime ES2350495T3 (es) 2005-04-06 2006-04-05 Forma cristalina de un compuesto de quinolinona-carboxamida.

Country Status (29)

Country Link
US (4) US7728004B2 (https=)
EP (1) EP1874766B1 (https=)
JP (2) JP5230407B2 (https=)
KR (1) KR101322873B1 (https=)
CN (1) CN101151264B (https=)
AR (2) AR053208A1 (https=)
AT (1) ATE479682T1 (https=)
AU (1) AU2006232129B2 (https=)
BR (1) BRPI0610657A2 (https=)
CA (1) CA2603654C (https=)
CY (1) CY1111275T1 (https=)
DE (1) DE602006016586D1 (https=)
DK (1) DK1874766T3 (https=)
EA (1) EA012115B1 (https=)
ES (1) ES2350495T3 (https=)
HR (1) HRP20100629T1 (https=)
IL (1) IL186023A (https=)
MA (1) MA29403B1 (https=)
MX (1) MX2007012438A (https=)
MY (1) MY151075A (https=)
NO (1) NO339699B1 (https=)
NZ (1) NZ561900A (https=)
PE (1) PE20061310A1 (https=)
PL (1) PL1874766T3 (https=)
PT (1) PT1874766E (https=)
SI (1) SI1874766T1 (https=)
TW (1) TWI377206B (https=)
WO (1) WO2006108127A2 (https=)
ZA (1) ZA200708071B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
AU2008254999A1 (en) * 2007-05-17 2008-11-27 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
SI2225230T1 (sl) * 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA2758321A1 (en) 2009-04-13 2010-10-21 Theravance, Inc. 5-ht4 receptor agonist compounds for treatment of cognitive disorders
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
BR112020000482A2 (pt) 2017-07-31 2020-07-21 Theravance Biopharma R&D Ip, Llc métodos de tratamento de sintomas de gastroparesia usando velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
EP4590303A1 (en) * 2022-09-20 2025-07-30 Alfasigma S.p.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
EP0670319A4 (en) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
DE602004026095D1 (de) 2003-11-24 2010-04-29 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
KR101322873B1 (ko) 2013-10-30
EA200702161A1 (ru) 2008-04-28
CN101151264A (zh) 2008-03-26
US7728004B2 (en) 2010-06-01
EP1874766A2 (en) 2008-01-09
DE602006016586D1 (de) 2010-10-14
WO2006108127A2 (en) 2006-10-12
HK1110866A1 (en) 2008-07-25
TW200643020A (en) 2006-12-16
MY151075A (en) 2014-03-31
US9126994B2 (en) 2015-09-08
US20160095849A1 (en) 2016-04-07
PT1874766E (pt) 2010-11-30
ATE479682T1 (de) 2010-09-15
EA012115B1 (ru) 2009-08-28
KR20070116988A (ko) 2007-12-11
US20060229332A1 (en) 2006-10-12
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
TWI377206B (en) 2012-11-21
NO20075574L (no) 2007-11-02
JP5230407B2 (ja) 2013-07-10
PL1874766T3 (pl) 2011-02-28
JP2008535848A (ja) 2008-09-04
AR053208A1 (es) 2007-04-25
NZ561900A (en) 2010-12-24
CN101151264B (zh) 2011-07-06
PE20061310A1 (es) 2007-01-23
WO2006108127A3 (en) 2007-01-04
AU2006232129A1 (en) 2006-10-12
AU2006232129B2 (en) 2012-07-12
ZA200708071B (en) 2008-10-29
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
SI1874766T1 (sl) 2010-12-31
MX2007012438A (es) 2007-12-05
IL186023A0 (en) 2008-01-20
US20140256769A1 (en) 2014-09-11
MA29403B1 (fr) 2008-04-01
BRPI0610657A2 (pt) 2010-07-13
CY1111275T1 (el) 2015-08-05
AR110019A2 (es) 2019-02-13
CA2603654A1 (en) 2006-10-12
JP2012153725A (ja) 2012-08-16
HRP20100629T1 (hr) 2010-12-31
US20100197728A1 (en) 2010-08-05
NO339699B1 (no) 2017-01-23
IL186023A (en) 2011-09-27
CA2603654C (en) 2014-05-27

Similar Documents

Publication Publication Date Title
ES2350495T3 (es) Forma cristalina de un compuesto de quinolinona-carboxamida.
ES2320907T3 (es) Compuestos de quinolinona-carboxamida como agonistas de receptores 5-ht4.
ES2327142T3 (es) Compuestos de quinolinona-carboxamida.
ES2359673T3 (es) Compuestos de benzoimidazolona-carboxamida como agonista del receptor 5-ht4.
BRPI0807974B1 (pt) Forma de sal cristalino, composiçao farmaceutica, processo para a preparaqao de um sal cristalino, aduto e uso da forma de sal cristalino
ES2376115T3 (es) Compuestos bencimidazol-carboxamida útiles como agonistas del receptor 5-ht4.
US8288550B2 (en) Crystalline form of a benzimidazole-carboxamide medicinal compound
ES2523851T3 (es) Compuestos de quinolinona como agonistas de los receptores 5-HT4
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
ES2336952T3 (es) Compuesto de carbamato como agonistas del recepttor 5-ht4.
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound